http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Quasi-static cyclic displacement pattern for seismic evaluation of reinforced concrete columns
Yuksel, E.,Surmeli, M. Techno-Press 2011 Structural Engineering and Mechanics, An Int'l Jou Vol.37 No.3
Although earthquakes generate random cyclic lateral loading on structures, a quasi-static cyclic loading pattern with gradually increasing amplitude has been commonly used in the laboratory tests because of its relatively low cost and simplicity compared with pseudo-dynamic and shake table tests. The number, amplitudes and sequence of cycles must be chosen appropriately as important parameters of a quasi-static cyclic loading pattern in order to account for cumulative damage matter. This paper aims to reach a new cyclic displacement pattern to be used in quasi-static tests of well-confined, flexure-dominated reinforced concrete (RC) columns. The main parameters of the study are sectional dimensions, percentage of longitudinal reinforcement, axial force intensity and earthquake types, namely, far-fault and near-fault.
Duran, Ayse Ocak,Karaca, Halit,Besiroglu, Mehmet,Bayoglu, Ibrahim Vedat,Menekse, Serkan,Yapici, Heves Surmeli,Yazilitas, Dogan,Bahceci, Aykut,Uysal, Mukremin,Sevinc, Alper,Hacibekiroglu, Ilhan,Aksoy, Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.23
Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC).The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n=298) received XELOX-Bev and Group 2 (n=111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%), stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95%CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95%CI; 16.8-23.1) for Group 2 (p=0.036). Median PFS was 9.6 months (range 2-36 months, 95%CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95%CI; 7.4-10.5) for Group 2 (p=0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p<0.001). Conclusions: First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev.